PlexinD1 Is a Driver and a Therapeutic Target in Advanced Prostate Cancer

Scientists identified the axon guidance semaphorin receptor PlexinD1 as a crucial driver of cancer aggressiveness in metastatic CRPC. High PlexinD1 expression in human prostate cancer was correlated with adverse clinical outcomes.